Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/considerations-when-choosing-oral-chemotherapy-identifying-and-awyslV0WpE
References (38)
-
F. Jansman, M. Postma, David Hartskamp, P. Willemse, J. Brouwers (2004)
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.Clinical therapeutics, 26 4
-
Geoffrey Liu, E. Franssen, M. Fitch, E. Warner (1997)
Patient preferences for oral versus intravenous palliative chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 1
-
E. Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, Michaela Jahn, J. Mckendrick, B. Osterwalder, G. Pérez-Manga, R. Rosso, P. Rougier, W. Schmiegel, J. Seitz, P. Thompson, J. Viéitez, C. Weitzel, P. Harper (2001)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 21
-
P. Hoff, R. Ansari, G. Batist, J. Cox, W. Kocha, M. Kuperminc, J. Maroun, D. Walde, C. Weaver, Evelyn Harrison, H. Burger, B. Osterwalder, A. Wong, Ralf Wong (2001)
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 8
-
A. Gramont, J. Bosset, Chantal Milan, P. Rougier, O. Bouché, P. Etienne, F. Morvan, C. Louvet, T. Guillot, E. François, L. Bedenne (1997)
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 2
-
M. Borner, P. Schöffski, R. Wit, F. Caponigro, G. Comella, A. Sulkes, G. Greim, G. Peters, K. Born, J. Wanders, R. Boer, C. Martín, P. Fumoleau (2002)
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.European journal of cancer, 38 3
-
L. Saltz, J. Cox, C. Blanke, L. Rosen, L. Fehrenbacher, M. Moore, J. Maroun, S. Ackland, P. Locker, N. Pirotta, G. Elfring, L. Miller (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.The New England journal of medicine, 343 13
-
R. Poorter, F. Lauw, W. Bemelman, P.J.M. Bakker, C. Taat, C.H.N. Veenhof (1996)
Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy.European journal of cancer, 32A 13
-
L. Floren, I. Bekersky, L. Benet, Q. Mekki, D. Dressler, Jeansun Lee, J. Roberts, M. Hebert (1997)
Tacrolimus oral bioavailability doubles with coadministration of ketoconazoleClinical Pharmacology & Therapeutics, 62
-
S. Weingart, Elizabeth Brown, P. Bach, K. Eng, Shirley Johnson, T. Kuzel, T. Langbaum, R. Leedy, R. Muller, L. Newcomer, Susan O'Brien, D. Reinke, M. Rubino, L. Saltz, R. Walters (2008)
NCCN Task Force Report: Oral chemotherapy.Journal of the National Comprehensive Cancer Network : JNCCN, 6 Suppl 3
-
A. Partridge, J. Avorn, Philip Wang, E. Winer (2002)
Adherence to therapy with oral antineoplastic agents.Journal of the National Cancer Institute, 94 9
-
J. Cassidy, J. Douillard, C. Twelves, J. Mckendrick, W. Scheithauer, I. Bustová, P. Johnston, K. Leśniewski-Kmak, S. Jelić, G. Fountzilas, F. Coxon, E. Díaz-Rubio, T. Maughan, A. Malzyner, O. Bertetto, A. Beham, A. Figer, P. Dufour, Patel Kk, W. Cowell, L. Garrison (2006)
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialBritish Journal of Cancer, 94
-
Chris Twelves, Michael Boyer, Michael Findlay, J. Cassidy, C. Weitzel, C. Barker, B. Osterwalder, C. Jamieson, K. Hieke (2001)
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.European journal of cancer, 37 5
-
R. James, C. Blanco, C. Farina (2003)
271 Savings in staff time as a result of switching from De Gramont to oral capecitabine for patients with advance colorectal cancer -
P. Piedbois (1992)
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 6
-
E. Cutsem, P. Hoff, P. Harper, R. Bukowski, D. Cunningham, P. Dufour, U. Graeven, J. Lokich, S. Madajewicz, J. Maroun, J. Marshall, E. Mitchell, G. Pérez-Manga, P. Rougier, W. Schmiegel, J. Schoelmerich, A. Sobrero, R. Schilsky (2004)
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsBritish Journal of Cancer, 90
-
J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzén, L. Saltz (2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 12
-
E. Yukawa, T. Honda, S. Ohdo, S. Higuchi, T. Aoyama (1997)
Population‐Based Investigation of Relative Clearance of Digoxin in Japanese Patients by Multiple Trough Screen Analysis: An UpdateThe Journal of Clinical Pharmacology, 37
-
R. Goldberg, D. Sargent, R. Morton, C. Fuchs, R. Ramanathan, S. Williamson, B. Findlay, H. Pitot, S. Alberts (2004)
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 1
-
W. Scheithauer, J. Mckendrick, S. Begbie, Markus Borner, W. Burns, H. Burris, J. Cassidy, Duncan Jodrell, P. Koralewski, E. Levine, N. Marschner, J. Maroun, P. García-Alfonso, J. Tujakowski, G. Hazel, A. Wong, J. Zaluski, Chris Twelves (2003)
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology, 14 12
-
E. Bajetta, M. Bartolomeo, L. Mariani, A. Cassata, S. Artale, S. Frustaci, G. Pinotti, A. Bonetti, I. Carreca, G. Biasco, L. Bonaglia, G. Marini, A. Iannelli, D. Cortinovis, E. Ferrario, E. Beretta, A. Lambiase, R. Buzzoni (2004)
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinomaCancer, 100
-
J. Lokich, J. Ahlgren, J. Gullo, James Philips, J. Fryer (1989)
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 4
-
S. Weingart, J. Flug, D. Brouillard, L. Morway, Ann Partridge, S. Bartel, L. Shulman, Maureen Connor (2007)
Oral chemotherapy safety practices at US cancer centres: questionnaire surveyBMJ : British Medical Journal, 334
-
A. Odani, Y. Hashimoto, K. Takayanagi, Y. Otsuki, T. Koue, M. Takano, M. Yasuhara, H. Hattori, K. Furusho, K. Inui (1996)
Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model.Biological & pharmaceutical bulletin, 19 3
-
K. Harrold (2010)
Effective management of adverse effects while on oral chemotherapy: implications for nursing practiceEuropean Journal of Cancer Care, 19
-
Y. Patt, J. Liebmann, D. Diamandidis, S. Eckhardt, M. Javle, G. Justice, W. Keiser, F. Lee, W. Miller, E. Lin (2004)
Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
-
(2011)
Gemcitabine in the Treatment of Non-small Cell Lung Cancer -
S. Payne (1992)
A study of quality of life in cancer patients receiving palliative chemotherapy.Social science & medicine, 35 12
-
Sharma (2001)
Patient selection for oral chemotherapyOncology (Williston Park, N.Y.), 15
-
A. Lebovits, J. Strain, M. Messe, S. Schleifer, J. Tanaka, S. Bhardwaj (1990)
Patient noncompliance with self‐administered chemotherapyCancer, 65
-
Di Costanzo (2006)
Italian economic evaluation of capecitabine vs. bolus 5-FU/LV as adjuvant chemotherapy for patients with Dukes' C colon cancerAnnals of Oncology, 17
-
Patt (2004)
Final efficacy and safety findings from a phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC)Annals of Oncology, 16
-
H. Mcleod, W. Evans (1999)
Oral cancer chemotherapy: the promise and the pitfalls.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 10
-
Markus Borner, Jacqueline Bernhard, Damien Dietrich, Razvan Popescu, Marie Wernli, P. Saletti, D. Rauch, Richard Herrmann, D. Koeberle, Hanspeter Honegger, Patrik Brauchli, Doris Lanz, Arnaud Roth (2005)
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.Annals of oncology : official journal of the European Society for Medical Oncology, 16 2
-
J. Cassidy, C. Twelves, E. Cutsem, P. Hoff, E. Bajetta, M. Boyer, R. Bugat, U. Burger, A. Garin, U. Graeven, J. Mckendrick, J. Maroun, J. Marshall, B. Osterwalder, G. Pérez-Manga, R. Rosso, P. Rougier, R. Schilsky (2002)
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.Annals of oncology : official journal of the European Society for Medical Oncology, 13 4
-
M. Maliepaard, M. Gastelen, A. Tohgo, Frederick Hausheer, R. Waardenburg, L. Jong, D. Pluim, J. Beijnen, J. Schellens (2001)
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 4
-
Mark DeMario, M. Ratain (1998)
Oral chemotherapy: rationale and future directions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 7
-
C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh, D. Mery-mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet, A. Gramont (2023)
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 41
- Publisher
- Wiley
- Copyright
- © 2010 The Authors. Journal compilation © 2010 Blackwell Publishing Ltd
- ISSN
- 0961-5423
- eISSN
- 1365-2354
- DOI
- 10.1111/j.1365-2354.2010.01199.x
- Publisher site
- See Article on Publisher Site
Abstract
IRSHAD S. & MAISEY N. (2010) European Journal of Cancer Care19, 5–11 Considerations when choosing oral chemotherapy: identifying and responding to patient need Oral chemotherapeutics are becoming increasingly accepted for the treatment of cancers and their future has never been brighter. They offer a more convenient and less invasive therapeutic option, moving cancer treatment from a predominantly hospital‐based day unit into the ambulatory setting. Oral chemotherapy has the potential to maintain patient's quality of life and avoid the complications and costs of intravenous chemotherapy. It offers sustained drug exposure by providing prolonged therapy compared with intermittent IV exposure and lends itself more easily to the delivery of combination therapy. In this article we highlight the expansion of oral chemotherapeutic drug development in cancer treatment and the challenges posed by this change in treatment delivery.
Journal
European Journal of Cancer Care – Wiley
Published: Jul 1, 2010